PMID- 18374328
OWN - NLM
STAT- MEDLINE
DCOM- 20081031
LR  - 20240312
IS  - 0014-2999 (Print)
IS  - 0014-2999 (Linking)
VI  - 585
IP  - 1
DP  - 2008 May 6
TI  - The substrates of memory: defects, treatments, and enhancement.
PG  - 2-13
LID - 10.1016/j.ejphar.2007.11.082 [doi]
AB  - Recent work has added strong support to the long-standing hypothesis that the 
      stabilization of both long-term potentiation and memory requires rapid 
      reorganization of the spine actin cytoskeleton. This development has led to new 
      insights into the origins of cognitive disorders, and raised the possibility that 
      a diverse array of memory problems, including those associated with diabetes, 
      reflect disturbances to various components of the same mechanism. In accord with 
      this argument, impairments to long-term potentiation in mouse models of 
      Huntington's disease and in middle-aged rats have both been linked to problems 
      with modulatory factors that control actin polymerization in spine heads. 
      Complementary to the common mechanism hypothesis is the idea of a single 
      treatment for addressing seemingly unrelated memory diseases. First tests of the 
      point were positive: Brain-Derived Neurotrophic Factor (BDNF), a potent activator 
      of actin signaling cascades in adult spines, rescued potentiation in Huntington's 
      disease mutant mice, middle-aged rats, and a mouse model of Fragile-X syndrome. A 
      similar reversal of impairments to long-term potentiation was obtained in 
      middle-aged rats by up-regulating BDNF production with brief exposures to 
      ampakines, a class of drugs that positively modulate AMPA-type glutamate 
      receptors. Work now in progress will test if chronic elevation of BDNF enhances 
      memory in normal animals.
FAU - Lynch, Gary
AU  - Lynch G
AD  - Department of Psychiatry and Human Behavior, University of California, Irvine CA, 
      United States.
FAU - Rex, Christopher S
AU  - Rex CS
FAU - Chen, Lulu Y
AU  - Chen LY
FAU - Gall, Christine M
AU  - Gall CM
LA  - eng
GR  - R01 NS051823/NS/NINDS NIH HHS/United States
GR  - T32 AG000096-21/AG/NIA NIH HHS/United States
GR  - R01 NS051823-07/NS/NINDS NIH HHS/United States
GR  - R01 NS037799-06/NS/NINDS NIH HHS/United States
GR  - R01 NS037799/NS/NINDS NIH HHS/United States
GR  - T32 AG000096/AG/NIA NIH HHS/United States
GR  - P01 NS045260-03/NS/NINDS NIH HHS/United States
GR  - NS37799/NS/NINDS NIH HHS/United States
GR  - P01 NS045260-04/NS/NINDS NIH HHS/United States
GR  - R01 NS037799-07/NS/NINDS NIH HHS/United States
GR  - T32 AG000258/AG/NIA NIH HHS/United States
GR  - NS045260/NS/NINDS NIH HHS/United States
GR  - P01 NS045260/NS/NINDS NIH HHS/United States
GR  - Z01 AG000258/ImNIH/Intramural NIH HHS/United States
GR  - NS051823/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
DEP - 20080304
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (Actins)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Nootropic Agents)
SB  - IM
MH  - Actins/physiology
MH  - Aging/physiology
MH  - Animals
MH  - Brain/physiopathology
MH  - Brain-Derived Neurotrophic Factor/physiology
MH  - Cytoskeleton/physiology
MH  - Dendritic Spines/physiology
MH  - Fragile X Syndrome/physiopathology
MH  - Humans
MH  - Huntington Disease/physiopathology
MH  - Learning/physiology
MH  - *Long-Term Potentiation
MH  - Memory/drug effects/*physiology
MH  - *Memory Disorders/drug therapy/physiopathology
MH  - Nootropic Agents/pharmacology/therapeutic use
MH  - Synapses/physiology
PMC - PMC2427007
MID - NIHMS50586
EDAT- 2008/04/01 09:00
MHDA- 2008/11/01 09:00
PMCR- 2009/05/06
CRDT- 2008/04/01 09:00
PHST- 2007/08/28 00:00 [received]
PHST- 2007/09/11 00:00 [revised]
PHST- 2007/11/29 00:00 [accepted]
PHST- 2008/04/01 09:00 [pubmed]
PHST- 2008/11/01 09:00 [medline]
PHST- 2008/04/01 09:00 [entrez]
PHST- 2009/05/06 00:00 [pmc-release]
AID - S0014-2999(08)00213-6 [pii]
AID - 10.1016/j.ejphar.2007.11.082 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 2008 May 6;585(1):2-13. doi: 10.1016/j.ejphar.2007.11.082. Epub 
      2008 Mar 4.